HC Wainwright Reaffirms “Buy” Rating for Capricor Therapeutics (NASDAQ:CAPR)

Capricor Therapeutics (NASDAQ:CAPR)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a report issued on Thursday,Benzinga reports. They presently have a $77.00 target price on the biotechnology company’s stock. HC Wainwright’s price target would suggest a potential upside of 393.27% from the company’s current price.

CAPR has been the subject of several other research reports. Cantor Fitzgerald increased their price target on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a research report on Thursday, November 14th. Maxim Group increased their target price on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a report on Wednesday, September 25th. Piper Sandler started coverage on Capricor Therapeutics in a report on Monday, October 21st. They set an “overweight” rating and a $35.00 price target on the stock. Finally, Oppenheimer reiterated an “outperform” rating and issued a $15.00 price objective on shares of Capricor Therapeutics in a report on Monday, September 23rd. One analyst has rated the stock with a sell rating and six have given a buy rating to the company. Based on data from MarketBeat.com, Capricor Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $34.50.

Capricor Therapeutics Stock Performance

Shares of CAPR stock opened at $15.61 on Thursday. The company has a market capitalization of $709.79 million, a P/E ratio of -14.73 and a beta of 3.98. Capricor Therapeutics has a fifty-two week low of $3.52 and a fifty-two week high of $23.40. The stock has a 50 day moving average price of $16.70 and a two-hundred day moving average price of $10.89.

Institutional Trading of Capricor Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of CAPR. Point72 Asset Management L.P. bought a new position in shares of Capricor Therapeutics in the 3rd quarter worth approximately $3,806,000. PFM Health Sciences LP purchased a new stake in Capricor Therapeutics in the third quarter worth $2,324,000. State Street Corp raised its holdings in Capricor Therapeutics by 27.8% in the third quarter. State Street Corp now owns 512,313 shares of the biotechnology company’s stock worth $7,792,000 after purchasing an additional 111,291 shares in the last quarter. Marshall Wace LLP purchased a new position in Capricor Therapeutics during the second quarter valued at $426,000. Finally, Renaissance Technologies LLC lifted its position in Capricor Therapeutics by 158.7% during the second quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock valued at $656,000 after buying an additional 84,350 shares during the period. 21.68% of the stock is currently owned by hedge funds and other institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.